Interview with Rob Durham (Gyros) on automation of assays and the Gyros Immunoassay

In this interview Rob Durham (Gyros) provides insight into his earlier work on biomarker development for neurodegeneration, detailing the benefits brought about by the use of the Gyros Immunoassay platform. Rob also provides his opinion on what he believes the future trends for assay automation will be.

Click here to view Gyros AB’s company profile.